Posters

Changes in corneal topography and biomechanical properties after collagen cross-linking for keratoconus: one year results

Poster Details

First Author: M.Bagheri IRAN

Co Author(s):    M. Sedaghat   S. Bamdad   S. Ghavami        

Abstract Details

Purpose:

To evaluate changes in corneal pachymetry, biomechanics, specular microscopy, and topography indices after collagen crosslinking (CXL) for keratoconus treatment.

Setting:

Khatam-alanbiya hospital, Mashad Ophthalmology Research Center, Mashad University of Medical Sciences, Mashad, Iran, with support from National Elit Foundation, Tehran, Iran

Methods:

CXL was performed on 97 eyes with progressive keratoconus. We assessed uncorrected and best corrected visual acuity, and refraction. Corneal topography indices were evaluated using placid disc corneal topography, scanning slit anterior topography (Orbscan II), and rotating Scheimpflug topography (Pentacam). Specular microscopy and corneal biomechanics were evaluated. Follow up was 6 and 12 months.

Results:

One year-follow up results showed that visual acuity, refraction, and surface keratometry improved significantly after CXL (P<0.05). Average keratometry value decreased from 49.62 to 47.95 D (P<0.001). Astigmatism decreased from 4.84 to 4.24 D (P<0.001). Apex corneal thickness decreased from 458.11 to 444.46 μm. Corneal volume decreased from 56.66 to 55.97 mm3 (P<0.001). Posterior best fit sphere increased from 55.50 to 46.03 mm (P=0.025). Posterior elevation increased from 99.2 to 112.22 μm (P<0.001). Average progressive index increased from 2.26 to 2.56 (P<0.001). A non-significant decrease in mean endothelial count from 2996 to 2928 cell/mm2 and also non-significant increase in endothelial coefficient of variation (CV) from 18.26 to 20.29 occurred after CXL. Corneal hysteresis changed from 8.18 to 8.36 and corneal resistance factor increased 6.98 to 7.21, though not significant.

Conclusions:

Visual acuity, refraction, and K values improve after CXL. In spite of the non-significant increase in endothelial cell count and increase in the CV, CLX seems a safe treatment for keratoconus, however further studies including more eyes and longer follow up period is recommended. FINANCIAL INTEREST: NONE